Alnylam Pharmace. buy Piper Sandler
Start price
31.10.25
/
50%
€395.60
Target price
31.10.26
€422.59
Performance (%)
-6.42%
Price
11:12
€370.20
Summary
This prediction is currently active. With a performance of -6.42%, the BUY prediction by Piper_Sandler is trending in the wrong direction. This prediction currently runs until 31.10.26. The prediction end date can be changed by Piper_Sandler at any time. Piper_Sandler has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Alnylam Pharmace. | -6.42% |
| iShares Core DAX® | -0.710% |
| iShares Nasdaq 100 | 1.556% |
| iShares Nikkei 225® | 4.150% |
| iShares S&P 500 | 0.738% |
Comments by Piper_Sandler for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its "overweight" rating reaffirmed by analysts at Piper Sandler. They now have a $489.00 price target on the stock, up previously from $449.00.
Ratings data for ALNY provided by MarketBeat
Stopped prediction by Piper_Sandler for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€169.60
14.12.23
14.12.23
€197.08
14.12.24
14.12.24
36.79%
15.12.24
15.12.24
